Symbols

BWAY

Brainsway·NASDAQ

--(--)

BWAY fundamentals

BWAY Q4 2025 Earnings

Brainsway (BWAY) released its earnings on Mar 11, 2026: revenue was 14.54M (YoY +27.43%), beat estimates; EPS was 0.035 (YoY +75.00%), beat estimates.

Revenue / YoY

14.54M

+27.43%

EPS / YoY

0.035

+75.00%

Report date

Mar 11, 2026

BWAY Earnings Call Summary for Q4,2025

Revenue Growth: Q4 2025 revenue up 27% YoY to $14.5 million, with full-year $52.2 million (27% YoY). RPO at $70 million (43% YoY growth).
FDA Expansion: Deep TMS cleared for adolescents (15-21) with MDD, targeting 5 million U.S. adolescents.
SWIFT Protocol: 70% reduction in clinic visits, with payer coverage from Premera and Highmark.
Strategic Investments: 5 mental health network investments, 200+ pipeline partners, and $11 million convertible loan with Neurolief for Proliv RX.
2026 Guidance: Revenue $66-68 million (27-30% YoY), adjusted EBITDA $12-14 million (86-100% YoY growth).

Earnings

EPS

Revenue

Revenue & Expenses

BWAY has released its 2025 Q4 earnings report, with revenue of 14.54M, reflecting a YoY change of 27.43%, and net profit of 2.93M, showing a YoY change of 89.47%. The Sankey diagram below clearly presents BWAY's revenue sources and cost distribution.

Key Indicators

Brainsway (BWAY) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Brainsway (BWAY)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Brainsway (BWAY)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Brainsway (BWAY)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown